Proton stereotactic body radiation therapy for liver metastases-results of 5-year experience for 81 hepatic lesions.

Autor:	Coffman AR; Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA., Sufficool DC; Department of Radiation Oncology, Kettering Health Network, Kettering, OH, USA., Kang JI; Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA., Hsueh CT; Department of Medical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA., Swenson S; Loma Linda University School of Medicine, Loma Linda, CA, USA., McGee PQ; Loma Linda University School of Medicine, Loma Linda, CA, USA., Nagaraj G; Department of Medical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA., Patyal B; Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA., Reeves ME; Department of Surgical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA., Slater JD; Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA., Yang GY; Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA.
Jazyk:	angličtina
Zdroj:	Journal of gastrointestinal oncology [J Gastrointest Oncol] 2021 Aug; Vol. 12 (4), pp. 1753-1760.
DOI:	10.21037/jgo-20-424
Abstrakt:	Background: To report on our institutional experience using Proton stereotactic body radiation therapy (SBRT) for patients with liver metastases. Methods: All patients with liver metastases treated with Proton SBRT between September 2012 and December 2017 were retrospectively analyzed. Local control (LC) and overall survival (OS) were estimated using the Kaplan-Meier method calculated from the time of completion of Proton SBRT. LC was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1). Toxicity was graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Results: Forty-six patients with 81 lesions were treated with Proton SBRT. The median age was 65.5 years old (range, 33-86 years) and the median follow up was 15 months (range, 1-54 months). The median size of the gross tumor volume (GTV) was 2.5 cm (range, 0.7-8.9 cm). Two or more lesions were treated in 56.5% of patients, with one patient receiving treatment to a total of five lesions. There were 37 lesions treated with a biologically effective dose (BED) ≤60, 9 lesions with a BED of 61-80, 22 lesions with a BED of 81-100, and 13 lesions with a BED >100. The 1-year and 2-year LC for all lesions was 92.5% (95% CI, 82.7% to 96.8%). The grade 1 and grade 2 toxicity rates were 37% and 6.5%, respectively. There were no grade 3 or higher toxicities and no cases of radiation-induced liver disease (RILD). Conclusions: Proton SBRT for the treatment of liver metastases has promising LC rates with the ability to safely treat multiple liver metastases. Accrual continues for our phase II trial treating liver metastases with Proton SBRT to 60 GyE (Gray equivalent) in 3 fractions. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at: http://dx.doi.org/10.21037/jgo-20-424). The authors have no conflicts of interest to declare. (2021 Journal of Gastrointestinal Oncology. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu